Tessera Therapeutics Attracts Over $230M in Series B Financing to Advance ‘Gene Writing’ – A New Category in Genetic Medicine

Jan 12, 2021•over 4 years ago

Amount Raised

$230 Million

Round Type

series b

Somerville

Description

Tessera Therapeutics, an early-stage life sciences company founded by Flagship Pioneering, announced today that it has raised over $230M in Series B financing. The round was co-led by Alaska Permanent Fund Corporation, Altitude Life Science Ventures, and SoftBank Vision Fund 2i, with participation from Qatar Investment Authority (QIA) and others.

Company Information

Company

Tessera Therapeutics

Location

Somerville, Pennsylvania, United States

About

Tessera Therapeutics is pioneering GENE WRITING technology, which consists of multiple technology platforms designed to offer scientists and clinicians the ability to write therapeutic messages into the human genome, thereby curing diseases at their source. The GENE WRITING platform allows the correction of single nucleotides, the deletion or insertion of short sequences of DNA, and the writing of entire genes into the genome, offering the potential for a new category of genetic medicines with broad applications both in vivo and ex vivo. Tessera Therapeutics was founded by Flagship Pioneering in 2018, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability. For more information about Tessera, please visit www.tesseratherapeutics.com.

FundzWatch™ Score

Medium Activity

Buyer Intent Analysis

Get personalized insights on buying likelihood

Funding Insights

Based on industry data

Tech investment trends